jCyte

jCyte, Inc. is a late-stage clinical biotechnology company focused on developing its first-class regenerative cell therapy, jCell, for the treatment of RP and other retinal degenerative diseases. Currently, there are no FDA-approved therapies for RP. The company is pioneering a new era of regenerative therapies to address the unmet medical needs of patients with various retinal degenerative diseases.